Identification

Name
Cimicoxib
Accession Number
DB05095
Type
Small Molecule
Groups
Investigational
Description

Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
W7FHJ107MC
CAS number
265114-23-6
Weight
Average: 381.809
Monoisotopic: 381.035017899
Chemical Formula
C16H13ClFN3O3S
InChI Key
KYXDNECMRLFQMZ-UHFFFAOYSA-N
InChI
InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
IUPAC Name
4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzene-1-sulfonamide
SMILES
COC1=C(F)C=C(C=C1)C1=C(Cl)N=CN1C1=CC=C(C=C1)S(N)(=O)=O

Pharmacology

Indication

Investigated for use/treatment in depression.

Pharmacodynamics
Not Available
Mechanism of action

Depression and schizophrenia are inflammatory diseases. Increased levels of pro-inflammatory cytokines and prostaglandin E (PGE) have repeatedly been described in major depression. COX-2 inhibitors inhibit production of both. Cimicoxib is a selective COX-2 inhibitor. The mechanism by which some COX-2 inhibitors work in depression could be linked to their anti-inflammatory mechanisms.

TargetActionsOrganism
UProstaglandin G/H synthase 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cimicoxib.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Cimicoxib.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cimicoxib.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Cimicoxib.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Cimicoxib.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Cimicoxib.Approved, Experimental, Investigational
AcenocoumarolCimicoxib may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Cimicoxib.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Cimicoxib.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Cimicoxib.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Cimicoxib.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Cimicoxib.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cimicoxib.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Cimicoxib.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Cimicoxib.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cimicoxib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Cimicoxib.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Cimicoxib.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Cimicoxib.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cimicoxib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Cimicoxib.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Cimicoxib.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Cimicoxib.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Cimicoxib.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cimicoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cimicoxib.Approved
BacitracinThe risk or severity of nephrotoxicity can be increased when Cimicoxib is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cimicoxib.Approved, Investigational
BazedoxifeneCimicoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Cimicoxib.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Cimicoxib.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Cimicoxib.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cimicoxib.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Cimicoxib.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Cimicoxib.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Cimicoxib.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cimicoxib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cimicoxib.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Cimicoxib.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cimicoxib.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Cimicoxib.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Cimicoxib.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Cimicoxib.Approved, Vet Approved, Withdrawn
CarvedilolCimicoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Cimicoxib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cimicoxib.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Cimicoxib.Approved, Investigational, Vet Approved
ChlorotrianiseneCimicoxib may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cimicoxib.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Cimicoxib.Approved, Investigational
CiprofloxacinCimicoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Cimicoxib.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Cimicoxib.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cimicoxib.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Cimicoxib.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Cimicoxib.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Cimicoxib.Approved
ClorindioneCimicoxib may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensCimicoxib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Cimicoxib.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Cimicoxib.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Cimicoxib.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Cimicoxib.Approved, Investigational
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Cimicoxib is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaidzeinCimicoxib may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Cimicoxib.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Cimicoxib.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Cimicoxib.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Cimicoxib.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Cimicoxib.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Cimicoxib.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Desvenlafaxine is combined with Cimicoxib.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cimicoxib.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Cimicoxib.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Cimicoxib.Approved, Vet Approved
DicoumarolCimicoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolCimicoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolCimicoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Cimicoxib.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Cimicoxib.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cimicoxib.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Cimicoxib.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Cimicoxib.Approved
DiphenadioneCimicoxib may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Cimicoxib.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Cimicoxib.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Cimicoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cimicoxib.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Cimicoxib.Investigational
EpimestrolCimicoxib may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Cimicoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Cimicoxib.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Cimicoxib.Approved
EquolCimicoxib may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Cimicoxib.Approved, Investigational
EstradiolCimicoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateCimicoxib may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateCimicoxib may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateCimicoxib may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolCimicoxib may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedCimicoxib may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneCimicoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Cimicoxib.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cimicoxib.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Cimicoxib.Experimental
Ethinyl EstradiolCimicoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateCimicoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Cimicoxib.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Cimicoxib.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Cimicoxib.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cimicoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Cimicoxib.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Cimicoxib.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Cimicoxib.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cimicoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Cimicoxib.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Cimicoxib.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Cimicoxib.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Cimicoxib.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Cimicoxib.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Cimicoxib.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cimicoxib.Approved, Investigational
FluindioneCimicoxib may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Cimicoxib.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Cimicoxib.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Cimicoxib.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Cimicoxib.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Cimicoxib.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Cimicoxib.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Cimicoxib.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Cimicoxib.Approved, Investigational
FluoxetineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Cimicoxib.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Cimicoxib.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Cimicoxib.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cimicoxib.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Cimicoxib.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Cimicoxib.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Cimicoxib.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Cimicoxib.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Cimicoxib.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Cimicoxib.Approved, Investigational, Withdrawn
GenisteinCimicoxib may increase the thrombogenic activities of Genistein.Investigational
GlipizideThe protein binding of Glipizide can be decreased when combined with Cimicoxib.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Cimicoxib.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Cimicoxib.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Cimicoxib.Investigational
HexestrolCimicoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Cimicoxib.Investigational
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Cimicoxib.Approved, Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Cimicoxib.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Cimicoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Cimicoxib.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Cimicoxib.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Cimicoxib.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Cimicoxib.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cimicoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cimicoxib.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cimicoxib.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Cimicoxib.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Cimicoxib.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Cimicoxib.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Cimicoxib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Cimicoxib.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Cimicoxib.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cimicoxib.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Cimicoxib.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cimicoxib.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Cimicoxib.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cimicoxib.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Cimicoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cimicoxib.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cimicoxib.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Cimicoxib.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cimicoxib.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Cimicoxib.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Cimicoxib.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Cimicoxib.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Cimicoxib.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cimicoxib.Approved
MestranolCimicoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cimicoxib.Approved, Investigational, Withdrawn
MethallenestrilCimicoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cimicoxib.Approved, Vet Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Cimicoxib.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cimicoxib.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Cimicoxib.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Cimicoxib.Approved, Vet Approved
MoxestrolCimicoxib may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cimicoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cimicoxib.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cimicoxib.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cimicoxib.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cimicoxib.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Cimicoxib.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Cimicoxib.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Cimicoxib.Approved, Withdrawn
NeomycinThe risk or severity of nephrotoxicity can be increased when Cimicoxib is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Cimicoxib.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Cimicoxib.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cimicoxib.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cimicoxib.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cimicoxib.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Cimicoxib.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cimicoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cimicoxib.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Cimicoxib.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cimicoxib.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cimicoxib.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cimicoxib.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Cimicoxib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Cimicoxib.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Cimicoxib.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Cimicoxib.Approved, Investigational
PhenindioneCimicoxib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCimicoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cimicoxib.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cimicoxib.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cimicoxib.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cimicoxib.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Cimicoxib.Experimental
Polyestradiol phosphateCimicoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Cimicoxib.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Cimicoxib.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Cimicoxib.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Cimicoxib.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cimicoxib.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Cimicoxib.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Cimicoxib.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Cimicoxib.Experimental
PromestrieneCimicoxib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cimicoxib.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Cimicoxib.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Cimicoxib.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Cimicoxib.Investigational
QuinestrolCimicoxib may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cimicoxib.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Cimicoxib.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Cimicoxib.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cimicoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cimicoxib.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cimicoxib.Approved
SecoisolariciresinolCimicoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Cimicoxib.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cimicoxib.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cimicoxib.Investigational
SertralineSertraline may increase the antiplatelet activities of Cimicoxib.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Cimicoxib.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cimicoxib.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Cimicoxib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Cimicoxib.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Cimicoxib.Experimental
Synthetic Conjugated Estrogens, ACimicoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BCimicoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cimicoxib.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Cimicoxib.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Cimicoxib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Cimicoxib.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Cimicoxib.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cimicoxib.Approved
TiboloneCimicoxib may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cimicoxib.Investigational
TioclomarolCimicoxib may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Cimicoxib.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cimicoxib.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cimicoxib.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Cimicoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Cimicoxib.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Cimicoxib.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Cimicoxib.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Cimicoxib.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cimicoxib.Approved, Investigational, Withdrawn
VenlafaxineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Venlafaxine is combined with Cimicoxib.Approved
WarfarinCimicoxib may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cimicoxib.Approved, Investigational
ZeranolCimicoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Cimicoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Cimicoxib.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cimicoxib.Withdrawn
Food Interactions
Not Available

References

General References
  1. Chegaev K, Lazzarato L, Tosco P, Cena C, Marini E, Rolando B, Carrupt PA, Fruttero R, Gasco A: NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J Med Chem. 2007 Apr 5;50(7):1449-57. Epub 2007 Mar 3. [PubMed:17335184]
  2. Almansa C, Bartroli J, Belloc J, Cavalcanti FL, Ferrando R, Gomez LA, Ramis I, Carceller E, Merlos M, Garcia-Rafanell J: New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs. J Med Chem. 2004 Oct 21;47(22):5579-82. [PubMed:15481993]
External Links
PubChem Compound
213053
PubChem Substance
175426942
ChemSpider
184745
BindingDB
50131593
ChEBI
76127
ChEMBL
CHEMBL435381
Wikipedia
Cimicoxib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.018 mg/mLALOGPS
logP3.21ALOGPS
logP2.12ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.8ChemAxon
pKa (Strongest Basic)3.69ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.21 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity103.72 m3·mol-1ChemAxon
Polarizability35.53 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8514
Caco-2 permeable+0.5426
P-glycoprotein substrateNon-substrate0.8067
P-glycoprotein inhibitor INon-inhibitor0.8166
P-glycoprotein inhibitor IINon-inhibitor0.8338
Renal organic cation transporterNon-inhibitor0.8166
CYP450 2C9 substrateNon-substrate0.6906
CYP450 2D6 substrateNon-substrate0.7202
CYP450 3A4 substrateNon-substrate0.548
CYP450 1A2 substrateNon-inhibitor0.7055
CYP450 2C9 inhibitorInhibitor0.7067
CYP450 2D6 inhibitorNon-inhibitor0.8442
CYP450 2C19 inhibitorInhibitor0.6281
CYP450 3A4 inhibitorNon-inhibitor0.6542
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8298
Ames testNon AMES toxic0.6842
CarcinogenicityNon-carcinogens0.7004
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4869 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8934
hERG inhibition (predictor II)Non-inhibitor0.5473
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Phenylimidazoles
Alternative Parents
Benzenesulfonamides / Benzenesulfonyl compounds / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers / Fluorobenzenes / Organosulfonamides / Aryl chlorides / Aryl fluorides
show 10 more
Substituents
5-phenylimidazole / 1-phenylimidazole / 4-phenylimidazole / Benzenesulfonamide / Benzenesulfonyl group / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Halobenzene
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, aromatic ether, sulfonamide, imidazoles, organochlorine compound (CHEBI:76127)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Almansa C, Bartroli J, Belloc J, Cavalcanti FL, Ferrando R, Gomez LA, Ramis I, Carceller E, Merlos M, Garcia-Rafanell J: New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs. J Med Chem. 2004 Oct 21;47(22):5579-82. [PubMed:15481993]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chegaev K, Lazzarato L, Tosco P, Cena C, Marini E, Rolando B, Carrupt PA, Fruttero R, Gasco A: NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J Med Chem. 2007 Apr 5;50(7):1449-57. Epub 2007 Mar 3. [PubMed:17335184]

Drug created on October 21, 2007 16:23 / Updated on August 02, 2018 05:29